De‐Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion‐dependent myelodysplastic syndromes

N, et al. Immunologically silent cancer clone transmission from mother to offspring. Proc Natl Acad Sci USA. 2009;106:17882–5. 7. Maruko K, Maeda T, Kamitomo M, Hatae M, Sueyoshi K. Transplacental transmission of maternal B-cell lymphoma. Am J Obstet Gynecol. 2004;191:380–1. 8. Osada S, Horibe K, Oiwa K, Yoshida J, Iwamura H, Matsuoka H, et al. A case of infantile acute monocytic leukemia caused by vertical transmission of the mother’s leukemic cells. Cancer. 1990;65:1146–9. 9. del Campo AB, Kyte JA, Carretero J, Zinchencko S, Mendez R, GonzalezAseguinolaza G, et al. Immune escape of cancer cells with beta2microglobulin loss over the course of metastatic melanoma. Int J Cancer. 2014;134:102–13. 10. McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259–71.

[1]  H. Leitch,et al.  Delayed time from RBC transfusion dependence to first cardiac event in lower IPSS risk MDS patients receiving iron chelation therapy. , 2019, Leukemia research.

[2]  A. Savic,et al.  Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry , 2019, Haematologica.

[3]  P. Greenberg,et al.  Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study , 2018, Blood.

[4]  D. Swinkels,et al.  Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes , 2017, Haematologica.

[5]  J. Arnaud,et al.  Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes , 2017, Oncotarget.

[6]  P. Fenaux,et al.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes , 2012, Haematologica.

[7]  D. Steensma,et al.  Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Ganser,et al.  Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. , 2010, Leukemia research.

[9]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[10]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Gordon Johnston,et al.  Statistical Models and Methods for Lifetime Data , 2003, Technometrics.